Drug Standards
Selleck Chemical LLC Decernotinib (VX-509) 2mg 944842-54-0
Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with Ki of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. Phase 2/3. *For Research & Development use only. Product is not intended for drug, household, or human consumption.
eMolecules 325775-44-8 | tert-butyl 3-(aminomethyl)azetidine-1-carboxylate | Pharmablock | MFCD01861762 | 186.255 | C9H18N2O2 | 97.000 | CC(C)(C)OC(=O)N1CC(CN)C1 | 25mg | 551054426
tert-butyl 3-(aminomethyl)azetidine-1-carboxylate | Pharmablock | 325775-44-8 | MFCD01861762 | 186.255 | C9H18N2O2 | 97.000 | CC(C)(C)OC(=O)N1CC(CN)C1 | 25mg | 551054426
Sigma Aldrich Fine Chemicals Biosciences Cyclosporine Resolution Mixture United States Pharmacopeia (USP) Reference Standard | 25MG
Cyclosporine Resolution Mixture United States Pharmacopeia (USP) Reference Standard | 25MG
Medchemexpress LLC Voriconazole | 137234-62-9 | 99.9% | C16H14F3N5O | 50 MG
Voriconazole (UK-109496) is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. It exerts its antifungal activity by inhibition of 14-alpha-lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes. It can penetrate the blood brain barrier (BBB).
- Second-generation, broad-spectrum triazole antifungal agent
- Inhibits fungal ergosterol biosynthesis
- Inhibits 14-alpha-lanosterol demethylation
- Mediated by fungal cytochrome P450 enzymes
- Penetrates the blood brain barrier (BBB)
- Active against S. apiospermum and C. neoformans
- Disrupts cell membrane and halts fungal growth
Medchemexpress LLC Voriconazole-d3 | 1217661-14-7 | 99.9% | C16H11D3F3N5O | 1 MG
Voriconazole-d3 is the deuterium labeled Voriconazole. Voriconazole (UK-109496) is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. It exerts its antifungal activity by inhibiting 14-α-lanosterol demethylation, a process mediated by fungal cytochrome P450 enzymes.
- Can be used as a tracer.
- Can be utilized as an internal standard for quantitative analysis through methods such as NMR, GC-MS, or LC-MS.
- Stable heavy isotopes, including deuterium, have been incorporated into drug molecules as tracers for quantitation during drug development.
- Deuteration can influence the pharmacokinetic and metabolic profiles of drugs.
Apexbio Technology LLC Divalproex Sodium 76584-70-8 50mg
Divalproex Sodium (CAS 76584-70-8) is a small-molecule inhibitor targeting histone deacetylases (HDACs) and modulating GABAergic neurotransmission It is designed to inhibit HDACs and modulate associated signaling pathways thereby regulating neuronal excitability and gene expression Divalproex Sodium exerts its biological activity primarily through HDAC inhibition enhancement of GABA levels inhibition of voltage-gated sodium channels and modulation of NMDA receptor-mediated glutamatergic signaling In experimental studies Divalproex Sodium demonstrates HDAC inhibitory activity with reported IC50 values typically ranging between 400 600 M varying by assay Based on these pharmacological properties Divalproex Sodium holds research potential in epilepsy bipolar disorder and migraine prophylaxis
Apexbio Technology LLC Milrinone 78415-72-2 100mg
Milrinone (CAS 78415-72-2) is a selective inhibitor of phosphodiesterase 3 (PDE3) demonstrating an IC50 of 56 12 nM for PDE3 inhibition It acts on both PDE3A localized predominantly in cardiac tissue vascular smooth muscle and platelets and PDE3B found in adipose tissue liver and pancreatic islets Milrinone increases intracellular cAMP levels in platelets with an EC50 of 5329 970 nM leading to enhanced contractility and vasodilation effects This profile supports its utility in cardiovascular research and metabolic studies involving cAMP-mediated signaling pathways
TARGETMOL CHEMICALS INC Plerixafor octahydrochloride 2
Also available in 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg and bulk. Please contact Fisher for quotes. Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. Purity 99.96%